dostęp otwarty

Tom 14, Nr 3 (2018)
Wytyczne / stanowisko ekspertów
Opublikowany online: 2018-11-21
Pobierz cytowanie

Postępowanie w tikach i zespole Gillesa de la Tourette’a — rekomendacje grupy ekspertów

Piotr Janik, Tomasz Wolańczyk, Anita Bryńska, Marcin Żarowski, Katarzyna Szamburska-Lewandowska, Natalia Szejko
Pol. Przegl. Neurol 2018;14(3):131-150.

dostęp otwarty

Tom 14, Nr 3 (2018)
Rekomendacje i zalecenia ekspertów
Opublikowany online: 2018-11-21

Streszczenie

Tiki to gwałtowne, szybkie, nawracające i nierytmiczne ruchy (tiki ruchowe) lub wokalizacje (tiki głosowe). Tiki są stałym objawem zespołu Gillesa de la Tourette’a (GTS, Gilles de la Tourette syndrome), z którymi często współistnieją zaburzenia psychiatryczne. W pracy przedstawiono epidemiologię, patofizjologię, naturalny przebieg, kryteria diagnostyczne, symptomatologię, rokowanie i różnicowanie w GTS. Głównym celem prezentowanych rekomendacji interdyscyplinarnej grupy ekspertów jest przedstawienie postępowania terapeutycznego i sposobów leczenia tików u dzieci i osób dorosłych z GTS.

Streszczenie

Tiki to gwałtowne, szybkie, nawracające i nierytmiczne ruchy (tiki ruchowe) lub wokalizacje (tiki głosowe). Tiki są stałym objawem zespołu Gillesa de la Tourette’a (GTS, Gilles de la Tourette syndrome), z którymi często współistnieją zaburzenia psychiatryczne. W pracy przedstawiono epidemiologię, patofizjologię, naturalny przebieg, kryteria diagnostyczne, symptomatologię, rokowanie i różnicowanie w GTS. Głównym celem prezentowanych rekomendacji interdyscyplinarnej grupy ekspertów jest przedstawienie postępowania terapeutycznego i sposobów leczenia tików u dzieci i osób dorosłych z GTS.

Pobierz cytowanie

Słowa kluczowe

tiki; terapia behawioralna; neuroleptyki; aripiprazol; klonidyna

Informacje o artykule
Tytuł

Postępowanie w tikach i zespole Gillesa de la Tourette’a — rekomendacje grupy ekspertów

Czasopismo

Polski Przegląd Neurologiczny

Numer

Tom 14, Nr 3 (2018)

Typ artykułu

Wytyczne / stanowisko ekspertów

Strony

131-150

Data publikacji on-line

2018-11-21

Rekord bibliograficzny

Pol. Przegl. Neurol 2018;14(3):131-150.

Słowa kluczowe

tiki
terapia behawioralna
neuroleptyki
aripiprazol
klonidyna

Autorzy

Piotr Janik
Tomasz Wolańczyk
Anita Bryńska
Marcin Żarowski
Katarzyna Szamburska-Lewandowska
Natalia Szejko

Referencje (76)
  1. Leckman JF, Cohen DJ. eds. Tourette’s syndrome tics, obsessions, compulsions. John Wiley & Sons, New York 1998.
  2. Kane MJ. Premonitory urges as. J Am Acad Child Adolesc Psychiatry. 1994; 33(6): 805–808.
  3. O’Connor K. Cognitive-behavioral management of tic disorders. Cognitive-behavioral management of tic disorders. John Wiley & Sons, New York 2008.
  4. Cath DC, Hedderly T, Ludolph AG, et al. ESSTS Guidelines Group. European clinical guidelines for Tourette syndrome and other tic disorders. Part I: assessment. Eur Child Adolesc Psychiatry. 2011; 20(4): 155–171.
  5. Karp BI, Hallett M. Extracorporeal 'phantom' tics in Tourette's syndrome. Neurology. 1996; 46(1): 38–40.
  6. Bliss J. Sensory experiences of Gilles de la Tourette syndrome. Arch Gen Psychiatry. 1980; 37(12): 1343–1347.
  7. Cheung MYC, Shahed J, Jankovic J. Malignant Tourette syndrome. Mov Disord. 2007; 22(12): 1743–1750.
  8. Sambrani T, Jakubovski E, Müller-Vahl KR. New insights into clinical characteristics of Gilles de la Tourette syndrome: findings in 1032 patients from a single German center. Front Neurosci. 2016; 10: 415.
  9. Knight T, Steeves T, Day L, et al. Prevalence of tic disorders: a systematic review and meta-analysis. Pediatr Neurol. 2012; 47(2): 77–90.
  10. Stefanoff P, Wolanczyk T, Gawrys A, et al. Prevalence of tic disorders among schoolchildren in Warsaw, Poland. Eur Child Adolesc Psychiatry. 2008; 17(3): 171–178.
  11. O'Rourke JA, Scharf JM, Yu D, et al. The genetics of Tourette syndrome: a review. J Psychosom Res. 2009; 67(6): 533–545.
  12. Price RA, Kidd KK, Cohen DJ, et al. A twin study of Tourette syndrome. Arch Gen Psychiatry. 1985; 42(8): 815–820.
  13. Hanna PA, Janjua FN, Contant CF, et al. Bilineal transmission in Tourette syndrome. Neurology. 1999; 53(4): 813–818.
  14. McMahon WM, van de Wetering BJ, Filloux F, et al. Bilineal transmission and phenotypic variation of Tourette's disorder in a large pedigree. J Am Acad Child Adolesc Psychiatry. 1996; 35(5): 672–680.
  15. Snider LA, Swedo S. Post-streptococcal autoimmune disorders of the central nervous system. Curr Opin Neurol. 2003; 16(3): 359–365.
  16. Murphy TK, Kurlan R, Leckman J. The immunobiology of Tourette's disorder, pediatric autoimmune neuropsychiatric disorders associated with Streptococcus, and related disorders: a way forward. J Child Adolesc Psychopharmacol. 2010; 20(4): 317–331.
  17. Leckman JF, King RA, Gilbert DL, et al. Streptococcal upper respiratory tract infections and exacerbations of tic and obsessive-compulsive symptoms: a prospective longitudinal study. J Am Acad Child Adolesc Psychiatry. 2011; 50(2): 108–118.e3.
  18. Leckman JF, Dolnansky ES, Hardin MT, et al. Perinatal factors in the expression of Tourette's syndrome: an exploratory study. J Am Acad Child Adolesc Psychiatry. 1990; 29(2): 220–226.
  19. Burd L, Severud R, Klug MG, et al. Prenatal and perinatal risk factors for Tourette disorder. J Perinat Med. 1999; 27(4): 295–302.
  20. Leckman JF. Phenomenology of tics and natural history of tic disorders. Brain Dev. 2003; 25(Suppl 1): S24–S28.
  21. Robertson MM. The prevalence and epidemiology of Gilles de la Tourette syndrome. J Psychosom Res. 2008; 65(5): 461–472.
  22. Janik P, Milanowski L, Szejko N. [Psychogenic tics: clinical characteristics and prevalence]. Psychiatr Pol. 2014; 48(4): 835–845.
  23. Robertson MM. The Gilles de la Tourette syndrome: the current status. Arch Dis Child Educ Pract Ed. 2012; 97(5): 166–175.
  24. Leckman JF, Bloch MH, Scahill L, et al. Tourette syndrome: the self under siege. J Child Neurol. 2006; 21(8): 642–649.
  25. Leckman JF, Zhang H, Vitale A, et al. Course of tic severity in Tourette syndrome: the first two decades. Pediatrics. 1998; 102(1 Pt 1): 14–19.
  26. Kostanecka-Endress T, Banaschewski T, Kinkelbur J, et al. Disturbed sleep in children with Tourette syndrome: a polysomnographic study. J Psychosom Res. 2003; 55(1): 23–29.
  27. Kirov R, Kinkelbur J, Banaschewski T, et al. Sleep patterns in children with attention-deficit/hyperactivity disorder, tic disorder, and comorbidity. J Child Psychol Psychiatry. 2007; 48(6): 561–570.
  28. Ghosh D, Rajan PV, Das D, et al. Sleep disorders in children with Tourette syndrome. Pediatr Neurol. 2014; 51(1): 31–35.
  29. Młodzikowska-Albrecht J, Zarowski M, Steinborn B. The symptomatology of tic disorders and concomitant sleep habits in children. Adv Med Sci. 2007; 52(Suppl 1): 212–214.
  30. Nussey C, Pistrang N, Murphy T. How does psychoeducation help? A review of the effects of providing information about Tourette syndrome and attention-deficit/hyperactivity disorder. Child Care Health Dev. 2013; 39(5): 617–627.
  31. Yates R, Edwards K, King J, et al. Habit reversal training and educational group treatments for children with tourette syndrome: A preliminary randomised controlled trial. Behav Res Ther. 2016; 80: 43–50.
  32. Verdellen C, van de Griendt J, Hartmann A, et al. ESSTS Guidelines Group. European clinical guidelines for Tourette syndrome and other tic disorders. Part III: behavioural and psychosocial interventions. Eur Child Adolesc Psychiatry. 2011; 20(4): 197–207.
  33. McGuire JF, Piacentini J, Scahill L, et al. Bothersome tics in patients with chronic tic disorders: characteristics and individualized treatment response to behavior therapy. Behav Res Ther. 2015; 70: 56–63.
  34. McGuire JF, Piacentini J, Brennan EA, et al. A meta-analysis of behavior therapy for Tourette syndrome. J Psychiatr Res. 2014; 50: 106–112.
  35. Leckman JF, Riddle MA, Hardin MT, et al. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry. 1989; 28(4): 566–573.
  36. Azrin NH, Nunn RG. Habit-reversal: a method of eliminating nervous habits and tics. Behav Res Ther. 1973; 11(4): 619–628.
  37. Watson TS, Sterling HE. Brief functional analysis and treatment of a vocal tic. J Appl Behav Anal. 1998; 31(3): 471–474.
  38. Kabat-Zinn J. An outpatient program in behavioral medicine for chronic pain patients based on the practice of mindfulness meditation: theoretical considerations and preliminary results. Gen Hosp Psychiatry. 1982; 4(1): 33–47.
  39. Reese HE, Vallejo Z, Rasmussen J, et al. Mindfulness-based stress reduction for Tourette syndrome and chronic tic disorder: a pilot study. J Psychosom Res. 2015; 78(3): 293–298.
  40. Murphy T, Heyman I. Group Work in Young People with Tourette Syndrome. Child and Adolescent Mental Health. 2007; 12(1): 46–48.
  41. Hilty DM, Ferrer DC, Parish MB, et al. The effectiveness of telemental health: a 2013 review. Telemed J E Health. 2013; 19(6): 444–454.
  42. Taylor C, Greenhalgh J, Stark D, et al. C2.1 Delivery of behavioural interventions for tics in an intensive outpatient format followed by remote delivery: a uk paediatric case series. Arch Dis Child. 2017; 102(Suppl 3): A11–A11.
  43. Lupton D, Maslen S. Telemedicine and the senses: a review. Sociol Health Illn. 2017; 39(8): 1557–1571.
  44. Schapiro E, Shapiro E. Treatment of tic disorders with haloperidol. In: Cohen DJ, Bruun RD, Leckman JF. ed. Tourette syndrome and tic disorders. John Wiley and Sons, New York 1998: 267–280.
  45. Martino D, Pringsheim TM. Tourette syndrome and other chronic tic disorders: an update on clinical management. Expert Rev Neurother. 2018; 18(2): 125–137.
  46. Sallee F, Kohegyi E, Zhao J, et al. Randomized, double-blind, placebo-controlled trial demonstrates the efficacy and safety of oral aripiprazole for the treatment of Tourette's disorder in children and adolescents. J Child Adolesc Psychopharmacol. 2017; 27(9): 771–781.
  47. Yoo HK, Joung YS, Lee JS, et al. A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette's disorder. J Clin Psychiatry. 2013; 74(8): e772–e780.
  48. Ghanizadeh A, Haghighi A. Aripiprazole versus risperidone for treating children and adolescents with tic disorder: a randomized double blind clinical trial. Child Psychiatry Hum Dev. 2014; 45(5): 596–603.
  49. Scahill L, Leckman JF, Schultz RT, et al. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology. 2003; 60(7): 1130–1135.
  50. Zheng Yi, Zhang ZJ, Han XM, et al. A proprietary herbal medicine (5-Ling Granule) for Tourette syndrome: a randomized controlled trial. J Child Psychol Psychiatry. 2016; 57(1): 74–83.
  51. George MS, Trimble MR, Robertson MM. Fluvoxamine and sulpiride in comorbid obsessive–compulsive disorder and gilles de la tourette syndrome. Hum Psychopharmacol Clin Exp. 1993; 8(5): 327–34.
  52. Eggers C, Rothenberger A, Berghaus U. Clinical and neurobiological findings in children suffering from tic disease following treatment with tiapride. Eur Arch Psychiatry Neurol Sci. 1988; 237(4): 223–229.
  53. Sallee FR, Kurlan R, Goetz CG, et al. Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry. 2000; 39(3): 292–299.
  54. Weisman H, Qureshi IA, Leckman JF, et al. Systematic review: pharmacological treatment of tic disorders — efficacy of antipsychotic and alpha-2 adrenergic agonist agents. Neurosci Biobehav Rev. 2013; 37(6): 1162–1171.
  55. Roessner V, Schoenefeld K, Buse J, et al. Pharmacological treatment of tic disorders and Tourette syndrome. Neuropharmacology. 2013; 68: 143–149.
  56. Müller-Vahl KR, Krueger D. Does Tourette syndrome prevent tardive dyskinesia? Mov Disord. 2011; 26(13): 2442–2443.
  57. Pringsheim T, Doja A, Gorman D, et al. Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy. Can J Psychiatry. 2012; 57(3): 133–143.
  58. Quezada J, Coffman KA. Current approaches and new developments in the pharmacological management of Tourette syndrome. CNS Drugs. 2018; 32(1): 33–45.
  59. Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009; 302(16): 1765–1773.
  60. Du Ys, Li Hf, Vance A, et al. Randomized double-blind multicentre placebo-controlled clinical trial of the clonidine adhesive patch for the treatment of tic disorders. Aust N Z J Psychiatry. 2008; 42(9): 807–813.
  61. Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry. 2001; 158(7): 1067–1074.
  62. Cummings DD, Singer HS, Krieger M, et al. Neuropsychiatric effects of guanfacine in children with mild tourette syndrome: a pilot study. Clin Neuropharmacol. 2002; 25(6): 325–332.
  63. Murphy TK, Fernandez TV, Coffey BJ, et al. Extended-release guanfacine does not show a large effect on tic severity in children with chronic tic disorders. J Child Adolesc Psychopharmacol. 2017; 27(9): 762–770.
  64. Jankovic J, Jimenez-Shahed J, Brown LW. A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry. 2010; 81(1): 70–73.
  65. Jankovic J, Glaze DG, Frost JD. Effect of tetrabenazine on tics and sleep of Gilles de la Tourette's syndrome. Neurology. 1984; 34(5): 688–692.
  66. Jankovic J, Jimenez-Shahed J, Budman C, et al. Deutetrabenazine in tics associated with Tourette syndrome. Tremor Other Hyperkinet Mov (N Y). 2016; 6: 422.
  67. Marras C, Andrews D, Sime E, et al. Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial. Neurology. 2001; 56(5): 605–610.
  68. Schrock LE, Mink JW, Woods DW, et al. Tourette Syndrome Association International Deep Brain Stimulation (DBS) Database and Registry Study Group. Tourette syndrome deep brain stimulation: a review and updated recommendations. Mov Disord. 2015; 30(4): 448–471.
  69. Baldermann JC, Schüller T, Huys D, et al. Deep brain stimulation for Tourette-syndrome: a systematic review and meta-analysis. Brain Stimul. 2016; 9(2): 296–304.
  70. Kefalopoulou Z, Zrinzo L, Jahanshahi M, et al. Bilateral globus pallidus stimulation for severe Tourette's syndrome: a double-blind, randomised crossover trial. Lancet Neurol. 2015; 14(6): 595–605.
  71. Welter ML, Houeto JL, Thobois S, et al. STIC study group. Anterior pallidal deep brain stimulation for Tourette's syndrome: a randomised, double-blind, controlled trial. Lancet Neurol. 2017; 16(8): 610–619.
  72. Ackermans L, Duits A, van der Linden C, et al. Double-blind clinical trial of thalamic stimulation in patients with Tourette syndrome. Brain. 2011; 134(Pt 3): 832–844.
  73. Okun MS, Foote KD, Wu SS, et al. A trial of scheduled deep brain stimulation for Tourette syndrome: moving away from continuous deep brain stimulation paradigms. JAMA Neurol. 2013; 70(1): 85–94.
  74. Maciunas RJ, Maddux BN, Riley DE, et al. Prospective randomized double-blind trial of bilateral thalamic deep brain stimulation in adults with Tourette syndrome. J Neurosurg. 2007; 107(5): 1004–1014.
  75. Servello D, Zekaj E, Saleh C, et al. Deep brain stimulation in Gilles de la Tourette syndrome: what does the future hold? A cohort of 48 patients. Neurosurgery. 2016; 78(1): 91–100.
  76. Servello D, Sassi M, Gaeta M, et al. Tourette syndrome (TS) bears a higher rate of inflammatory complications at the implanted hardware in deep brain stimulation (DBS). Acta Neurochir (Wien). 2011; 153(3): 629–632.

Ważne: serwis https://journals.viamedica.pl/ wykorzystuje pliki cookies. Więcej >>

Używamy informacji zapisanych za pomocą plików cookies m.in. w celach statystycznych, dostosowania serwisu do potrzeb użytkownika (np. język interfejsu) i do obsługi logowania użytkowników. W ustawieniach przeglądarki internetowej można zmienić opcje dotyczące cookies. Korzystanie z serwisu bez zmiany ustawień dotyczących cookies oznacza, że będą one zapisane w pamięci komputera. Więcej informacji można znaleźć w naszej Polityce prywatności.

Czym są i do czego służą pliki cookie możesz dowiedzieć się na stronie wszystkoociasteczkach.pl.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel. +48 58 320 94 94, faks +48 58 320 94 60, e-mail: viamedica@viamedica.pl